In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases

Daniela Fioretti, Sandra Iurescia, Vito Michele Fazio, Monica Rinaldi

Research output: Contribution to journalArticle

Abstract

Electroporation is the process commonly referred to the transient increase in the permeability of cell membranes on submission to electric field pulses. Electroporation has become an increasingly extensive method to enhance in vivo DNA delivery for both gene therapy applications as well as for delivery of DNA vaccines, mostly against cancer. In vivo gene electrotransfer is of special interest since it is the most efficient non-viral strategy for gene delivery and it is worthy of low manufacturing costs, ease of realization and favorable safety profile. No adverse findings observed in toxicology and biodistribution/integration studies have been warranted for the evaluation of this approach in humans. Therefore, gene delivery followed by electroporation is currently being investigated in several clinical trials. The positive outcomes of early studies suggest that the efficacy of gene delivery and immunogenicity has greatly improved by electroporation. This review briefly summarizes salient features and recent findings that have contributed to the rapid progress of electroimmunotherapy as well as an overview of advanced clinical studies in oncology. Translation of in vivo DNA electrovaccination for neurodegenerative diseases as well as future expectations are also discussed.

Original languageEnglish
Pages (from-to)279-290
Number of pages12
JournalCurrent Drug Metabolism
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Neurodegenerative diseases
Electroporation
Neurodegenerative Diseases
Immunotherapy
Genes
DNA
Neoplasms
Cell Membrane Permeability
Gene therapy
DNA Vaccines
Oncology
Cell membranes
Genetic Therapy
Toxicology
Electric fields
Outcome Assessment (Health Care)
Clinical Trials
Safety
Costs and Cost Analysis
Costs

Keywords

  • Cancer
  • Clinical studies
  • DNA electrotransfer
  • Electroimmunotherpay
  • Electrovaccination
  • Neurodegenerative diseases

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases. / Fioretti, Daniela; Iurescia, Sandra; Fazio, Vito Michele; Rinaldi, Monica.

In: Current Drug Metabolism, Vol. 14, No. 3, 03.2013, p. 279-290.

Research output: Contribution to journalArticle

Fioretti, Daniela ; Iurescia, Sandra ; Fazio, Vito Michele ; Rinaldi, Monica. / In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases. In: Current Drug Metabolism. 2013 ; Vol. 14, No. 3. pp. 279-290.
@article{83421711feb741b8b3654080c593867d,
title = "In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases",
abstract = "Electroporation is the process commonly referred to the transient increase in the permeability of cell membranes on submission to electric field pulses. Electroporation has become an increasingly extensive method to enhance in vivo DNA delivery for both gene therapy applications as well as for delivery of DNA vaccines, mostly against cancer. In vivo gene electrotransfer is of special interest since it is the most efficient non-viral strategy for gene delivery and it is worthy of low manufacturing costs, ease of realization and favorable safety profile. No adverse findings observed in toxicology and biodistribution/integration studies have been warranted for the evaluation of this approach in humans. Therefore, gene delivery followed by electroporation is currently being investigated in several clinical trials. The positive outcomes of early studies suggest that the efficacy of gene delivery and immunogenicity has greatly improved by electroporation. This review briefly summarizes salient features and recent findings that have contributed to the rapid progress of electroimmunotherapy as well as an overview of advanced clinical studies in oncology. Translation of in vivo DNA electrovaccination for neurodegenerative diseases as well as future expectations are also discussed.",
keywords = "Cancer, Clinical studies, DNA electrotransfer, Electroimmunotherpay, Electrovaccination, Neurodegenerative diseases",
author = "Daniela Fioretti and Sandra Iurescia and Fazio, {Vito Michele} and Monica Rinaldi",
year = "2013",
month = "3",
doi = "10.2174/1389200211314030003",
language = "English",
volume = "14",
pages = "279--290",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - In vivo DNA electrotransfer for immunotherapy of cancer and neurodegenerative diseases

AU - Fioretti, Daniela

AU - Iurescia, Sandra

AU - Fazio, Vito Michele

AU - Rinaldi, Monica

PY - 2013/3

Y1 - 2013/3

N2 - Electroporation is the process commonly referred to the transient increase in the permeability of cell membranes on submission to electric field pulses. Electroporation has become an increasingly extensive method to enhance in vivo DNA delivery for both gene therapy applications as well as for delivery of DNA vaccines, mostly against cancer. In vivo gene electrotransfer is of special interest since it is the most efficient non-viral strategy for gene delivery and it is worthy of low manufacturing costs, ease of realization and favorable safety profile. No adverse findings observed in toxicology and biodistribution/integration studies have been warranted for the evaluation of this approach in humans. Therefore, gene delivery followed by electroporation is currently being investigated in several clinical trials. The positive outcomes of early studies suggest that the efficacy of gene delivery and immunogenicity has greatly improved by electroporation. This review briefly summarizes salient features and recent findings that have contributed to the rapid progress of electroimmunotherapy as well as an overview of advanced clinical studies in oncology. Translation of in vivo DNA electrovaccination for neurodegenerative diseases as well as future expectations are also discussed.

AB - Electroporation is the process commonly referred to the transient increase in the permeability of cell membranes on submission to electric field pulses. Electroporation has become an increasingly extensive method to enhance in vivo DNA delivery for both gene therapy applications as well as for delivery of DNA vaccines, mostly against cancer. In vivo gene electrotransfer is of special interest since it is the most efficient non-viral strategy for gene delivery and it is worthy of low manufacturing costs, ease of realization and favorable safety profile. No adverse findings observed in toxicology and biodistribution/integration studies have been warranted for the evaluation of this approach in humans. Therefore, gene delivery followed by electroporation is currently being investigated in several clinical trials. The positive outcomes of early studies suggest that the efficacy of gene delivery and immunogenicity has greatly improved by electroporation. This review briefly summarizes salient features and recent findings that have contributed to the rapid progress of electroimmunotherapy as well as an overview of advanced clinical studies in oncology. Translation of in vivo DNA electrovaccination for neurodegenerative diseases as well as future expectations are also discussed.

KW - Cancer

KW - Clinical studies

KW - DNA electrotransfer

KW - Electroimmunotherpay

KW - Electrovaccination

KW - Neurodegenerative diseases

UR - http://www.scopus.com/inward/record.url?scp=84877950434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877950434&partnerID=8YFLogxK

U2 - 10.2174/1389200211314030003

DO - 10.2174/1389200211314030003

M3 - Article

C2 - 23116113

AN - SCOPUS:84877950434

VL - 14

SP - 279

EP - 290

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 3

ER -